The role of zinc in the anti-tumour and anti-cachectic activity of D-myo-inositol 1,2,6-triphosphate by Russell, Steven et al.
The role of zinc in the anti-tumour and anti-cachectic activity of
D-myo-inositol 1,2,6-triphosphate
ST Russell1, PMA Siren2, MJ Siren2,3 and MJ Tisdale*,1
1Nutritional Biomedicine, School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK; 2Bioneris Ab, IAM, Adolf Fredriks Kyrkogata 13,
Stockholm 11137, Sweden; 3JGK Memorial Research Library and Laboratory, Helsinki To¨o¨lo¨n k 1900260, Finland
BACKGROUND: D-myo-inositol-1,2,6-triphosphate (a-trinositol, AT) is a polyanionic molecule capable of chelating divalent metal ions
with anti-tumour and anti-cachectic activity in a murine model.
METHODS: To investigate the role of zinc in this process, mice bearing cachexia-inducing MAC16 tumour were treated with AT, with
or without concomitant administration of ZnSO4.
RESULTS: At a dose of 40mg kg1, AT effectively attenuated both weight loss and growth of the MAC16 tumour, and both effects
were attenuated by co-administration of Zn2þ . The concentration of zinc in gastrocnemius muscle increased with increasing weight
loss, whereas administration of AT decreased the levels of zinc in plasma, skeletal muscle and tumour, which were restored back to
control values after administration of ZnSO4.
CONCLUSION: These results suggest that zinc is important in both tumour growth and cachexia in this animal model.
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Trace metals such as zinc are essential components of many
enzymes and transcription factors. Deficiency of zinc results in
reduced food intake and growth, impaired synthesis of DNA and
dysfunction of the immune system (MacDonald, 2000). Zinc has
been shown to be involved in intracellular signalling events
(Yamasaki et al, 2007), whereas an extracellular zinc-sensing
receptor, not requiring zinc influx, has been shown to trigger the
release of Ca2þ from intracellular stores (Hershfinkel et al, 2001).
Although zinc is an essential trace element, high concentrations
are toxic to cells, and zinc uptake, intracellular storage and efflux
are carefully maintained (Kim et al, 2004).
There is evidence for aberrant zinc transport into tumour cells,
and it has been suggested that zinc availability may be essential for
tumour growth (Lee et al, 2003). Overexpression of the zinc
transporter, ZIP4, compared with the surrounding normal tissue,
is seen in 94% of clinical specimens of pancreatic adenocarcinoma,
suggesting that it may contribute to the pathogenesis and
progression of the disease (Li et al, 2007). An increased expression
of ZIP4 in pancreatic cancer cells increased intracellular zinc
concentration, cell proliferation and tumour volume in nude mice.
Zinc has also been shown to induce a dose-dependent increase in
proliferation of the human prostate adenocarcinoma cell line,
PC-3, and this was attenuated by the zinc chelator Ca EDTA (Dubi
et al, 2008). Extracellular zinc also attenuated cell death. These
results suggest that zinc chelation may be an effective measure to
inhibit tumour growth.
There are also changes in zinc concentration in tumour and
skeletal muscle of rats bearing a methylcholanthrene-induced
fibrosarcoma during muscle wasting (Larsson et al, 1987). Thus, at
12 days after tumour transplantation, when cachexia is maximal,
there is a significant decrease in serum zinc concentration, with a
corresponding increase in both tumour and skeletal muscle.
A progressive decrease in plasma zinc was also observed during
growth of rat adenocarcinoma (Philcox et al, 1994). These results
suggest that zinc may also have a role in the process of atrophy of
skeletal muscle.
We have previously shown (Russell et al, 2009) that
the polyanionic compound D-myo-inositol 1,2,6-triphosphate
(a-trinositol, AT) attenuated both tumour growth and muscle
atrophy in mice bearing the cachexia-inducing MAC16 tumour.
a-Trinositol has been shown to chelate divalent metal ions such as
Ca2þ and Zn2þ , which bind to phosphates P1 and P6 of the
inositol ring structure (Falemez and Speiss, 2001), but there have
been no studies on whether this is important in the anti-cachectic
and anti-tumour effect of AT. We hypothesised (PS and MJS) that
zinc has an important role in the onset and progression of cancer
cachexia. The current study investigates the role of zinc in the
biological effects of AT in mice bearing the MAC16 tumour and its
relationship to tumour growth and cachexia
MATERIALS AND METHODS
Materials
D-myo-inositol 1,2,6-triphosphate (AT) was supplied by JGK
Memorial Research Library and Laboratory (Helsinki, Finland)/
Bioneris Ab (Stockholm, Sweden).
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Animals
The MAC16 tumour was passaged in pure strain male NMRI mice
(average weight 25 g), which were obtained from our own inbred
colony, and were fed a rat and mouse breeding diet (Special Diet
Services, Witham, UK) and water ad libitum. Tumour fragments
were obtained from donor animals selected as those having the
maximum weight loss, and were implanted s.c. into the flank by
means of a trochar, as previously described (Bibby et al, 1987).
Weight loss was evident from 10 days after tumour transplantation
and animals were entered into the study when they had lost B5%
of their starting body weight. Animals were randomised into
groups of five to receive either solvent (PBS), AT (40mg kg1) or
AT (40mg kg1) plus 8.05mg ZnSO4 in 25 ml PBS administered i.v.
1 h after AT. A fourth group received ZnSO4 alone. Both PBS and
AT were administered s.c. three times a day. Tumour volume, body
weight and food and water intake were monitored daily. Animals
were killed by cardiac puncture under terminal anaesthesia when
the body weight loss was at, or before, 20%, as approved by the
British Home Office. The ethical guidelines that were followed met
the standards required by the UKCCR guidelines (Workman et al,
1998). Both tumour and gastrocnemius muscles were removed,
snap frozen in liquid nitrogen and stored at 801C until
measurement of zinc concentration.
Measurement of zinc concentrations
Tissues were weighed in crucibles, which were previously washed
in 5% Lipsol, and rinsed with deionised bio-filtered water, followed
by trace analysis using nitric acid. The crucibles were placed in a
furnace at room temperature, and the temperature was increased
to 1501C for 1 h, then 6001C for 2 h, followed by 8001C overnight. A
fine white ash, free from organic material, was obtained, and the
crucibles were cooled and stored in desiccators. The crucibles were
subsequently re-weighed to obtain the mass of ash, which was
dissolved in 10ml of trace element analysis concentrated nitric
acid and sonicated for 30min to ensure stabilisation. The dissolved
ash was then transferred to a 100ml volumetric flask, which was
made up to volume with deionised bio-filtered water. The sample
was then analysed for zinc using a PerkinElmer Analyst 100 atomic
absorption spectrophotometer (PerkinElmer, Waltham, MA, USA),
at a wavelength of 213.9 nM, slit 0.7mm, using air/acetylene gas
and a lamp current of 10mA. Standards of known concentrations
were used to construct calibration curves from which the
concentration of zinc in the sample could be determined.
Statistical analysis
Results are presented as mean±s.e.m. Differences in means
between groups were determined by one-way analysis of variance
(ANOVA), followed by the Tukey–Kramer multiple comparison
test. P-values o0.05 were considered significant.
RESULTS
The effect of AT on body weight of mice bearing the MAC16
tumour is shown in Figure 1A. A dose of 40mg kg1 of AT was
chosen, as this has been shown to produce optimal inhibition of
both weight loss and tumour volume (Russell et al, 2009). This
study again showed that AT attenuated the loss of body weight
produced by the MAC16 tumour, and this was completely reversed
by administration of Zn2þ 1 h after AT. Administration of Zn2þ
alone had no effect on weight loss compared with that of PBS
controls. A similar result was obtained with regard to tumour
volume (Figure 1B). Thus, AT also attenuated the tumour growth
rate, and this was completely reversed by co-administration of
Zn2þ . However, Zn2þ alone inhibited tumour growth rate to the
same extent as AT. These results show the importance of Zn2þ in
the anti-cachectic and anti-tumour activity of AT.
As previously reported in weight-losing rats bearing a
fibrosarcoma (Larsson et al, 1987), there was an increase in zinc
concentration in the gastrocnemius muscle of mice bearing the
MAC16 tumour, which became significant when weight loss was
o18% (Figure 2). There was no difference in the zinc concentra-
tion of plasma between tumour-bearing and non-tumour-bearing
animals (Figure 3A). The reason for the accumulation of zinc in
skeletal muscle is not known. However, treatment of mice bearing
the MAC16 tumour with AT caused a significant reduction in zinc
concentration in the plasma (Figure 3A), gastrocnemius muscle
(Figure 3B) and tumour (Figure 3C), when measured after 4 days
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Figure 1 Weight change (A) and tumour volume (B) in either non-
tumour-bearing mice (’) or in mice bearing the MAC16 tumour treated
with either PBS (E), AT (m), AT þZn2þ (X) or Zn2þ (O) at the doses
and schedule as detailed in Materials and Methods. Differences from PBS-
treated animals are indicated as *Po0.01 or **Po0.001.
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Figure 2 Zinc concentrations in gastrocnemius muscle of non-tumour-
bearing mice and mice bearing the MAC16 tumour and with different
extents of weight loss. The results are expressed relative to non-tumour-
bearing animals after allowance for different muscle weights. Differences
from non-tumour-bearing animals are shown as *Po0.05.
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of treatment, as shown in Figure 1. Administration of Zn2þ to
animals receiving AT increased the levels of Zn2þ in plasma,
gastrocnemius muscle and tumour up to the levels found in PBS
controls (Figure 3), consistent with the ability of Zn2þ to attenuate
the action of AT on weight loss (Figure 1A) and tumour volume
(Figure 1B). Administration of Zn2þ in the absence of AT caused a
significant increase in the levels of Zn2þ in plasma, gastrocnemius
muscle and tumour (Figure 3), consistent with an increase in
weight loss and tumour volume (Figure 1). These results suggest
that both tumour growth and weight loss may be limited by the
availability of Zn2þ .
DISCUSSION
The results of this study show the importance of Zn2þ in the
process of both muscle wasting and tumour growth in mice
bearing the MAC16 tumour. There have been few studies on the
role of Zn2þ in skeletal muscle atrophy, although an increase in
Zn2þ has been observed in the skeletal muscle of rats during the
progress of cachexia (Larsson et al, 1987), as also observed in this
study in mice bearing the MAC16 tumour. A similar result was
obtained in mice transplanted with the Lewis Lung Carcinoma,
which also produces cachexia (Frank et al, 1986). In this study, the
zinc concentration in muscle was three times that of normal
control, and there was also a re-distribution to the bone. One
mechanism by which Zn2þ could participate in muscle atrophy is
through activation of nuclear factor-kB (NF-kB) through phos-
phorylation of p65/Rel A at multiple serine residues (Kim et al,
2007). Activation of NF-kB in the muscle of mice has been shown
to lead to atrophy through increased expression of proteasome
subunits and the E3 ligase, MURF1 (Cai et al, 2004). It occurs
through activation of caspases-3 and -8, and the subsequent
autophosphorylation of the dsRNA-dependent protein kinase
(PKR) (Suen et al, 2003). Autophosphorylation of PKR in skeletal
muscle has been shown to inhibit protein synthesis owing to
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Figure 3 Concentration of zinc in plasma (A), gastrocnemius muscle (B) and tumour (C) of mice bearing the MAC16 tumour after 4 days of treatment
with PBS, AT, AT plus Zn2þ or Zn2þ alone, as depicted in Figure 1. Differences from PBS controls are shown as *Po0.05 or **Po0.01, whereas
differences from AT are shown as wPo0.05 and differences from ATþZn as zPo0.05 or yPo0.01.
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phosphorylation of eukaryotic initiation factor-2 (eIF2) on the
a-subunit, and increased protein degradation through the NF-kB-
mediated induction of the ubiquitin–proteasome pathway
(Eley and Tisdale, 2007). The activity of caspases-3 and -8,
phosphorylation of PKR and eIF2a and the activity and expression
of the ubiquitin–proteasome pathway have been shown to be
attenuated by AT in mice bearing the MAC16 tumour (Russell
et al, 2009).
These results provide some evidence that the attenuation of loss
of skeletal muscle by AT is separate from its anti-tumour activity,
although both effects seem to be due to its ability to chelate Zn2þ .
Studies in vitro also support a separate role of AT in attenuating
muscle atrophy. Thus, using murine myotubes as a model of
skeletal muscle, AT has been shown to attenuate both the
induction of protein degradation and depression of protein
synthesis induced by proteolysis-inducing factor, angiotensin II,
lipopolysaccharide and TNF-a (Russell et al, 2009 and unpublished
results), and these effects could be reversed by addition of Zn2þ .
These studies also suggest that Zn2þ is required for the caspase-3/-8-
mediated activation of PKR. As AT is highly negatively charged,
it is unlikely that it would readily penetrate into cells; hence, it is
likely that the effects are mediated through the chelation of
extracellular Zn2þ .
In view of the potential mechanism by which AT attenuates
tumour growth rate by chelation of Zn2þ , and the role of zinc in
the proliferation of pancreatic cancer (Li et al, 2007), it was
surprising that administration of Zn2þ alone attenuated tumour
growth rate to the same extent as AT. However, it is known that
although tumours need Zn2þ to grow and survive, excess Zn may
induce apoptosis (Murakami and Hirano, 2008). Extracellular zinc
has been shown to regulate growth and survival of prostate cancer
cells through a putative zinc-sensing receptor (Dubi et al, 2008).
Low concentrations of Zn2þ were shown to stimulate cell
proliferation through activation of the mitogen-activated protein
kinase and phosphatidylinositol-3-kinase pathways mediated by
a Gq-coupled receptor. (Azriel-Tamir et al, 2004) However, high
concentrations of Zn2þ led to desensitisation of the zinc
receptor possibly through constitutive desensitisation, as for other
G-protein-coupled receptors, and through inhibition of tumour
growth. These results could explain the apparent anomaly that
both chelators of Zn2þ and Zn2þ itself inhibit tumour growth.
These results suggest that AT is a novel agent with anti-cachectic
and anti-tumour activity due to its ability to chelate Zn2þ . Further
studies are required on the role of Zn2þ in the signalling cascade
leading to muscle atrophy, in order to elucidate the mode of action
of this important metal in relation to cachexia.
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